Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06445166 | Propranolol for the Treatment of Kaposi Sarcoma in Adults | recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07032285 | Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas(CIRTUSARC) | recruiting | Phase 2 | 25 | Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasOTHER | 1 | Apr 6, 2026 |
| clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07007273 | Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma | recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06905132 | Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma | recruiting | Phase 2 | 40 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05152173 | Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis | completed | Phase 2 | 176 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03793361 | Phase II Study of Regorafenib as Maintenance Therapy(EREMISS) | completed | Phase 2 | 127 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01303094 | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma(T-DIS) | completed | Phase 2 | 53 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01612481 | Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma(CASSANDRE) | terminated | Phase 2 | 11 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05950594 | IVIM & OLINK in Sarcoma | recruiting | Phase 2 | 145 | University Health Network, TorontoOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05755113 | A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | recruiting | Phase 2 | 40 | QBiotics Group LimitedINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07457775 | Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS | not yet recruiting | Phase 2 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00186992 | Radiation Therapy to Treat Musculoskeletal Tumors | active not recruiting | Phase 2 | 202 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06815666 | BAL Fluid Biomarkers in Sarcoma | recruiting | Phase 2 | 70 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03602833 | Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma | completed | Phase 1 / Phase 2 | 12 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04305691 | Trial of Ixazomib for Kaposi Sarcoma | recruiting | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 27, 2026 | clinicaltrials |
| NCT01207492 | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | completed | Phase 2 | 17 | Andrew J. Wagner, MD, PhDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04288375 | Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs | active not recruiting | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03474094 | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy(RT-Immune) | active not recruiting | Phase 2 | 62 | Centre Leon BerardOTHER | 2 | Feb 10, 2026 | clinicaltrials |
| NCT06712433 | Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)(CONCERTO) | not yet recruiting | Phase 2 | 31 | Adam OlsonOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06630234 | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04562480 | Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk | active not recruiting | Phase 2 | 120 | Mayo ClinicOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT01391962 | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT04599062 | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | active not recruiting | Phase 1 / Phase 2 | 8 | John RiethOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | withdrawn | Phase 2 | 0 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 0 | Jan 22, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07342322 | A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma | not yet recruiting | Phase 2 | 25 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02805725 | Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide(TARMIC) | completed | Phase 1 / Phase 2 | 50 | Institut BergoniéOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06536517 | The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | recruiting | Phase 2 | 100 | Johns Hopkins UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | terminated | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00975819 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | completed | Phase 2 | 61 | Denise Martin AdamsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT06835049 | Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)(TNT-HYPE) | recruiting | Phase 2 | 24 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | recruiting | Phase 2 | 47 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03077451 | Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 36 | AIDS Malignancy ConsortiumNETWORK | 3 | Dec 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 6, 2026source: clinicaltrials